Ashwagandha for Nighttime Waking

NCT ID: NCT07151261

Last Updated: 2025-12-29

Basic Information

• Recruitment Status: RECRUITING
• Clinical Phase: NA
• Total Enrollment: 54 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2025-10-20
• Study Completion Date: 2026-03-31

Brief Summary

The purpose of this research is to evaluate the effect of a sustained-release, lower-dosage (150mg) Ashwagandha supplement to reduce disturbed sleep. 54 participants, after randomization, will take either an Ashwagandha supplement or a placebo daily for 28 days (week 4) and wear an Oura ring. The Oura ring will measure waking after sleep onset (WASO). Questionnaires to evaluate quality of life and sleep will be administered at baseline and week 4.

Detailed Description

Each participant will be in the study for about 5 weeks (1 preparation week and 4 weeks for the trial). Questionnaires consist of the Patient-Reported Outcomes Measurement Information System (PROMIS-29). Subjects will be screened for mild sleep disturbance using the PROMIS Sleep Disturbance questionnaire.

Conditions

Disturbed Sleep

Keywords

Ashwagandha; Disturbed Sleep; Waking After Sleep Onset; Oura ring

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: OTHER
• Blinding Strategy: TRIPLE

Study Groups

Sustained-Release Ashwagandha Supplement

Sustained-release, lower-dosage (150mg) Ashwagandha supplement; 1 capsule 1 time per day.

Group Type: EXPERIMENTAL

Ashwagandha

Intervention Type: DIETARY_SUPPLEMENT

Sustained-Release, lower-dosage (150mg) Ashwagandha Supplement, 1 capsule 1 time per day.

Placebo

Placebo Supplement: Consists of microcrystalline cellulose and is matched for shape, color, and smell. 1 capsule, 1 time per day.

Group Type: PLACEBO_COMPARATOR

Placebo

Intervention Type: OTHER

This placebo does not contain any of the interventional dietary supplement. The placebo consists of microcrystalline cellulose and is matched for shape, color, and smell. 1 capsule, 1 time per day.

Interventions

Ashwagandha

Sustained-Release, lower-dosage (150mg) Ashwagandha Supplement, 1 capsule 1 time per day.

Intervention Type: DIETARY_SUPPLEMENT

Placebo

This placebo does not contain any of the interventional dietary supplement. The placebo consists of microcrystalline cellulose and is matched for shape, color, and smell. 1 capsule, 1 time per day.

Intervention Type: OTHER

Other Intervention Names

Withania Somnifera

Eligibility Criteria

Inclusion Criteria

• Age: Male and non-pregnant female adult participants must be between 18 and 65 years of age.
• Female subjects of childbearing potential must be using a medically acceptable form of birth control, as there are unknown pregnancy risks when starting any new supplement.
• Female subjects of non-childbearing potential must be amenorrheic for at least 1 year or have had a hysterectomy and/or bilateral oophorectomy.
• Sleep Quality: Otherwise, healthy individuals with a raw score of 25-29 (T-score of approximately 55.0-59.9) on the Patient-Reported Outcomes Measurement Information System (PROMIS) Sleep Disturbance Short Form 8a, indicating at least mild sleep disturbance.
• Sleep Hygiene: Willing to follow basic sleep hygiene protocols (dark/dim lights, quiet location/white noise, regular sleep routine, abstaining from digital activity 1 hour prior to sleep) during the Baseline week and the 28-day trial.
• Wearable Device: Participants must be willing to comply with study procedures, including wearing the Oura Ring nightly (at least 4 nights per week) and completing questionnaires.
• Informed Consent: Participants must be able to provide informed consent and comply with the study procedure.
• Willing to wear the Oura Ring for a total of 35 days (7-day base + 28 days of trial)
• Willing to maintain current dietary patterns, activity level, and stable body weight for the duration of the study, and refrain from any drastic lifestyle changes.
• Willing to refrain from using sleep-promoting supplements or medications during the study, such as melatonin, antihistamines, valerian root, chamomile, magnesium, and cannabinoids (CBD).
• Results of screening procedures/ lab investigations are within normal range or considered not clinically significant by the Principal Investigator.
• Willing to undergo study procedures including safety lab tests and urine pregnancy test (UPT only for women of childbearing potential).

Exclusion Criteria

• Age: Participants younger than 18 and older than 65 years of age.
• Use of Medications: Current use of sleep-promoting or sleep-disrupting medications or supplements.
• Diagnosed Sleep Disorder: Sleep apnea, narcolepsy, or other for which they are taking medication.
• Other Conditions: Significant medical or psychiatric conditions that could interfere with sleep assessment.
• Irregular Sleep Schedules: Shift workers or those with irregular sleep schedules, as well as anyone with a newborn or having a lifestyle likely to interfere with sleep patterns (eg: jet lag).
• Pregnancy or Lactation: Individuals who are pregnant, lactating, or planning a pregnancy within the next 30 days.
• Post-menopausal female subjects on any Hormone Replacement Therapy
• Allergies: Known allergy or hypersensitivity to any component of the study product.
• Alcohol Intake: History or presence of excessive alcohol use (> 8 drinks per week in women and > 15 drinks per week in men within the past month) or use of recreational drugs (such as cocaine, methamphetamine, marijuana, etc.) or addiction to nicotine (current smokers/tobacco users)
• Chronic Illness: Participants with chronic conditions such as liver disease, kidney disease, or severe cardiovascular disease or cancer, colorectal disease and/or other rare disorders that at the discretion of the Principal Investigator (PI) or Clinical Investigator (CI) may impact their safety or confound trial results
• Other Medications: Subjects taking insulin, psychotropics, anxiolytics, sedatives, hypnotics or herbal supplements / Over the counter (OTC) product / multivitamins etc. for sleep or anxiety or any other psychological condition, or any other prescription product which has a known side effect of causing somnolence or sleep problems, within one month prior to the screening visit.
• High-risk medications: The use of any high-risk medications with narrow therapeutic indices metabolized by cytochrome (CYP450) enzymes: Warfarin (CYP2C9), Tacrolimus/Cyclosporine (CYP3A4), Efavirenz (CYP2B6), and Codeine (CYP2D6).
• Drugs requiring activation for efficacy: Clopidogrel (CYP2C19), Codeine (CYP2D6), and Tamoxifen (CYP2D6).
• Participation in Other Trials: Currently participating in another interventional research study or participated in another interventional research study within 90 days of screening
• Any condition that in opinion of the Investigator, does not justify the Subjects' participation in the study.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 65 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

National University of Natural Medicine

OTHER

Sponsor Role: lead

Responsible Party

Joshua Goldenberg

Principal Investigator

Responsibility Role: PRINCIPAL_INVESTIGATOR

Principal Investigators

Joshua Goldenberg, ND

Role: PRINCIPAL_INVESTIGATOR

National University of Natural Medicine

Locations

National University of Natural Medicine

Portland, Oregon, United States

Site Status: RECRUITING

Countries

United States

Central Contacts

Joshua Goldenberg, ND

Role: CONTACT

Phone: 503-552-1882

Email: jgoldenberg@nunm.edu

Carina A Staab, DC, MEd

Role: CONTACT

Email: cstaab@nunm.edu

Facility Contacts

Carina A Staab, DC, MEd

Role: primary

Joshua Goldenberg, ND

Role: backup

Other Identifiers

ES43025

Identifier Type: -

Identifier Source: org_study_id